top of page


RGCC is a specialist medical genetics company and leading expert in the field of cancer genetics, liquid biopsy, and chemosensitivity tests. They provide personalized cancer genetics tests for doctors and patients worldwide in their ISO-accredited laboratories, which are equipped with the latest technology and specialized software for data analysis.

They aim to detect any potential early signs of cancer, monitor existing cancers, and produce a personalized profile of chemotherapy drugs and natural treatments that could benefit individual patients.


RGCC Immune-Frame is used to assess the condition of a patient’s immune system. Scientists use the test to identify specific cellular markers that are responsible for switching a patient’s immune system on and off. The results of Immune-Frame can be used to analyze the status of a patient’s immune system, and to provide ongoing information about their health status. This information can be used by your medical provider to advise on potential health risks a patient may face, and how these can be minimized.

RGCC Metastat is an advanced test to detect specific blood-borne markers that can accurately determine whether a secondary cancerous tumor is likely to develop and its potential location. We analyze a sample to identify and measure circulating tumor cells (CTCs). Metastat RGCC is suitable for all patients who have received a confirmed cancer diagnosis. The test can accurately detect the development of secondary cancers or tumors and improve personalized cancer treatments.

RGCC Onconomics Plus provides information about the effect of specific anti-cancer drugs, targeted therapies, and natural treatments on the cancer cells in an individual patient. A sample of blood or tissue is analyzed to test how effective specific therapies and treatments are at suppressing cancer. Together, the results of the extensive tests provide your medical provider with a comprehensive breakdown of the most suitable and successful treatments for cancer. The results can be used to design personalized and targeted cancer therapies with the highest chances of success.

RGCC Oncotrail provides crucial information on the presence of circulating tumor cells (CTCs) and their concentration in patients who have a confirmed diagnosis of specific forms of cancer, including breast, colon and prostate cancer. The blood is analyzed to identify the presence and concentration of CTC and their immunophenotype. Oncotrail RGCC isn’t used as a primary diagnostic test to confirm a cancer diagnosis but provides essential information on the effectiveness of current cancer treatments. Follow-up tests can also be used to monitor a patient’s health and assess the risk of relapse.

RGCC Oncotrace is used to identify a primary tumor in a patient and to provide guidance about disease progression and future prognosis. The blood is analyzed to identify the presence and concentration of circulating tumor cells (CTCs) and their concentration. This test provides information about the presence of CTCs, their concentration, and specific type (immunophenotype). The results of the test enable clinicians to identify the origin of a tumor where this is unknown and to provide information on the development of cancer and the prognosis.

RGCC Oncocount detects the presence of circulating tumor cells (CTCs) and their concentration in the blood. CTCs are a powerful biomarker, and their presence in the blood can act as an early warning sign that cancer is returning. The test is designed as a follow-up test for patients who have cancer and are worried about the disease returning. Clinicians can use the Oncocount RGCC test to assess how effective cancer treatment is and the likelihood of cancer returning (relapse).

RGCC PaldiSpot test detects the presence of Borrelia, Babesia, and Bartonella genospecies in a DNA sample. Used in combination with our PrimeSpot test, the PaldiSpot test provides critical information for patients with Lyme Disease and chronic fatigue syndrome. The results can help your medical provider develop effective personalized treatment and therapies. The PaldiSpot test is clinically validated and highly accurate. It is suitable for adults aged 18 and over.

RGCC PrimeSpot test detects and quantifies specific viruses and Lyme Disease-associated species in a blood sample. When used in combination with the PaldiSpot test, the PrimeSpot test provides critical information that can inform the development of personalized treatments and therapies for Lyme Disease, chronic fatigue syndrome, and other medical conditions. The PrimeSpot test is clinically validated and highly accurate. It is suitable for adults aged 18 and over.


RGCC SOT (supportive oligonucleotide therapy) is a personalized therapy for cancer, viruses, and pathogens including Lyme Disease. The SOT has the ability to bind to a specific gene of interest that controls the cancer cell or pathogen by disrupting the critical process that promotes its survival or growth. A sample of your blood is sent to RGCC Lab and they create a complementary oligonucleotide sequence that is designed to interrupt the survival or growth of the cells. 

  • SOT treatment effectively silences the genes within cancer cells that are allowing the cancer cells to live. Your chromosomes contain genes which are strings of nucleotides.  These nucleotides are ‘read’ by RNA.  The RNA is then translated into proteins and this is how genes are expressed.

    • SOT is called ‘anti-sense’ which means it creates a string of nucleotides which bind to the RNA, rendering it ineffective, and therefore it cannot be translated into proteins. This will cause cell death (aka apoptosis) of circulating tumor cells and cancer stem cells in primary and metastatic tumors. 

    • Because it causes massive tumor cell destruction which can cause a potentially life-threatening condition called “tumor lysis syndrome”, there are some restrictions on using this treatment. 

    • For example, if a patient has widespread cancer, or a large tumor burden, in highly vascular areas such as the liver or lungs, that person may not be a candidate for SOT until the tumor burden can be reduced by, e.g., the vaccine treatment, other alternative therapies, or conventional chemotherapy, surgery, and/or radiation.

    • SOT is administered intravenously as a one-time dose, every 4 to 6 months.

    • The SOT remains active in the body for 24-28 weeks. The maximum dose is 3 full doses (or 6 half doses) for every 12 months. 

    • And even if a patient is unable to get his or her cancer cell count to zero, SOT can be used for years to control cancer.

The lab can make Cancer Vaccines, aka ATA (autologous tumor antigen), which are made up of antigens used by the body’s immune cells to determine what cells should be attacked or left alone.

    • Specific antigens are found on cancer cells in the patient’s blood and administered back to the patient intravenously or subcutaneously (under the skin).

      • This stimulates the immune system to attack the specific cancer cells in the body without harming the body’s normal cells. 

    • ATA is administered over 9 weeks, i.e. once a week for 3 weeks, then off for 3 weeks, and then once a week for another 3 weeks.

    • If needed, the protocol can be repeated 3 months after the last injection.


RGCC Vaxo-Q-Re is a new advanced therapy consisting of five types of immune cells; macrophages, NK cells, dendritic cells, cytotoxic T lymphocytes, and antibody-producing plasma cells. Tested on breast cancer cells but effective at treating all forms of the disease, the adoptive T cell-based therapy encourages the body’s immune system to target cancer cells. Vaxo-Q-Re has been in development by RGCC scientists for more than five years and is now categorized as a Cell Therapy Medicinal Product (CTMP) by the European Medicines Agency (EMA).

bottom of page